Collecting blood samples from patients treated with CAR-T cells for blood cancers
Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies in Montpellier University Hospital
This study is collecting blood samples from patients with lymphoma and Acute Lymphoblastic Leukemia who have been treated with CAR-T cells to see what factors affect how well the treatment works.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Montpellier Academic / other |
| Drugs / interventions | CAR-T |
| Locations | 1 site (Montpellier) |
| Trial ID | NCT04290000 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and bank blood samples from patients treated with CAR-T cells for hematological malignancies, specifically lymphoma and Acute Lymphoblastic Leukemia, at the University Hospital of Montpellier. The study will gather clinical data alongside the biological samples to investigate the factors influencing the efficacy of CAR-T cell treatments. By understanding the reasons behind treatment failures, the research seeks to optimize CAR-T cell therapies for better patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have been treated with CAR-T cells at the University Hospital of Montpellier.
Not a fit: Patients who may not benefit from this study include those who refuse to sign the consent form or are pregnant.
Why it matters
Potential benefit: If successful, this study could lead to improved CAR-T cell therapies and better treatment responses for patients with hematological malignancies.
How similar studies have performed: While CAR-T cell therapies have shown impressive outcomes in some studies, this specific approach to understanding treatment failures is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient treated by CAR-T cell at the University Hospital of Montpellier Exclusion Criteria: * refusal to sign consent form * pregnant woman * major protected
Where this trial is running
Montpellier
- Département d'hématologie clinique — Montpellier, France (Recruiting)
Study contacts
- Study coordinator: Sylvain LAMURE, MD
- Email: s-lamure@chu-montpellier.fr
- Phone: 0033467336733
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.